Merck wants the world to know that when it comes to developing new drugs for cardiovascular disease, the company is in the fight for the long haul.
At the American Heart Association’s annual scientific meeting underway now through Wednesday in New Orleans, the company is taking out “Heart of Merck” ads in the convention newspaper, showing a video on the topic at its booth in the exhibit hall, and talking to reporters about its commitment to what has been one of the most beneficial and lucrative franchises in the history of the drug industry.
“We have a legacy, we have this core competency,” Dick Pasternak, Merck’s vice president for cardiovascular clinical research, told the Health Blog over a cup of coffee in the Crescent City. “We have a responsibility to the public to continue to fight the war against the biggest cause of death and disability.”
Discuss Add this link to... Bury
At the American Heart Association’s annual scientific meeting underway now through Wednesday in New Orleans, the company is taking out “Heart of Merck” ads in the convention newspaper, showing a video on the topic at its booth in the exhibit hall, and talking to reporters about its commitment to what has been one of the most beneficial and lucrative franchises in the history of the drug industry.
“We have a legacy, we have this core competency,” Dick Pasternak, Merck’s vice president for cardiovascular clinical research, told the Health Blog over a cup of coffee in the Crescent City. “We have a responsibility to the public to continue to fight the war against the biggest cause of death and disability.”
Discuss Add this link to... Bury
Comments